Compare MFA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFA | NVCR |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2015 |
| Metric | MFA | NVCR |
|---|---|---|
| Price | $10.27 | $12.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $11.05 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.2M | 981.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 13.91% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $10.02 | $6.74 |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $8.78 | $9.82 |
| 52 Week High | $10.57 | $20.05 |
| Indicator | MFA | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 52.05 |
| Support Level | $9.75 | $10.72 |
| Resistance Level | $10.33 | $13.30 |
| Average True Range (ATR) | 0.16 | 0.58 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 79.84 | 63.54 |
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.